News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Sandoz has joined biosimilar developers calling on the US FDA to provide clear guidance on interchangability just a day after launching Zarxio, its Neupogen (filgrastim) copycat.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
Michigan has introduced a Bill to allow pharmacists to substitute a reference biologic with a biosimilars deemed interchangeable by the FDA.